Results 4,781-4,800 of 12,424 for speaker:Louise O'Reilly

Written Answers — Department of Health: Addiction Treatment Services (15 May 2019)

Louise O'Reilly: 157. To ask the Minister for Health the number of addiction beds in the health service; and his plans to increase the number. [20969/19]

Written Answers — Department of Health: Health Services Reports (15 May 2019)

Louise O'Reilly: 158. To ask the Minister for Health if further consideration will be given to the need for an inquiry into foetal valproate syndrome as soon as the valproate response team of the HSE has completed its work; when this work is expected to be completed; and when he expects to further consider the matter. [20971/19]

Written Answers — Department of Health: Health Services Reports (15 May 2019)

Louise O'Reilly: 159. To ask the Minister for Health if he will meet a group (details supplied) and provide a clear answer to its request for an inquiry into accountability issues and compensation for those individuals and families already affected by foetal valproate syndrome. [20972/19]

Written Answers — Department of Health: Health Services Reports (15 May 2019)

Louise O'Reilly: 160. To ask the Minister for Health when his attention was drawn to the risks associated with the use of valproate in pregnancy; the action taken to minimise these risks in particular prior to 2014 when the European Medicines Agency implemented its first series of risk reduction measures; and his views on the recent study published in a journal (details supplied). [20973/19]

Written Answers — Department of Health: Health Services Reports (15 May 2019)

Louise O'Reilly: 162. To ask the Minister for Health the information available in respect of the prevalence of foetal valproate syndrome within the population. [20975/19]

Written Answers — Department of Health: Disability Services Provision (15 May 2019)

Louise O'Reilly: 161. To ask the Minister for Health if the healthcare assessment and needs of children suspected of having foetal valproate syndrome will be prioritised as a matter of urgency; and if there will be no delays in diagnosis and service provision [20974/19]

Written Answers — Department of Health: Medicinal Products Licensing (15 May 2019)

Louise O'Reilly: 163. To ask the Minister for Health the clinical trials conducted on sodium valproate here prior to its licensing in 1975; and if no clinical trials were conducted here, the international clinical trial data used as the basis for its approval. [20976/19]

Written Answers — Department of Health: Hospital Appointments Administration (15 May 2019)

Louise O'Reilly: 164. To ask the Minister for Health his views on whether it is acceptable that patients at some hospitals are being given only two days' notice to attend surgical appointments and if they miss the appointment they are then struck off the waiting list. [20977/19]

Written Answers — Department of Health: Medical Aids and Appliances Provision (15 May 2019)

Louise O'Reilly: 165. To ask the Minister for Health if his attention has been drawn to the fact that lymphedema patients are being charged for lymphedema garments that are essential garments for their treatment (details supplied); and if he will make a statement on the matter. [20978/19]

Joint Oireachtas Committee on Health: National Oral Health Policy: Discussion (15 May 2019)

Louise O'Reilly: I welcome the witnesses. I thank Professor Stassen, in particular, for coming in, since he operated on my daughter. This is the first time I have seen him since the very successful operation in St. James's Hospital, for which I thank him. I read the submissions, which are quite scary. As Deputy Donnelly said, it is rare that we would get submissions in which the language is so stark. The...

Joint Oireachtas Committee on Health: National Oral Health Policy: Discussion (15 May 2019)

Louise O'Reilly: That is regrettable for the witnesses.

Joint Oireachtas Committee on Health: National Oral Health Policy: Discussion (15 May 2019)

Louise O'Reilly: It is regrettable that the very people who are going to be on the front line of implementing any strategy are being excluded. I have my own view on why that would happen. We all share the same sentiment that it is regrettable that we are talking about a discussion document into which the witnesses had no input. On the number of vacant consultant posts, they gave information on the age...

Joint Oireachtas Committee on Health: National Oral Health Policy: Discussion (15 May 2019)

Louise O'Reilly: I thank Professor Lynch. I have one more question. I do not disbelieve the figures that show there is an unusually high level of extractions in Ireland, especially among young children or younger people. Notwithstanding the fact that the people who are material to the new strategy were left out of any meaningful discussion on it, do the delegates believe it will be possible to implement...

Joint Oireachtas Committee on Health: National Oral Health Policy: Discussion (15 May 2019)

Louise O'Reilly: I thank Professor Stassen. I apologise because I must leave to deal with questions in the Dáil Chamber. When they are finished, I will come back to the committee if it is still sitting.

Ceisteanna ó Cheannairí - Leaders' Questions (16 May 2019)

Louise O'Reilly: It is a class war.

Ceisteanna ar Reachtaíocht a Gealladh - Questions on Promised Legislation (16 May 2019)

Louise O'Reilly: He is entitled to an answer.

Written Answers — Department of Health: Cannabis for Medicinal Use (16 May 2019)

Louise O'Reilly: 113. To ask the Minister for Health further to Parliamentary Question Nos. 826 and 827 of 8 May 2019, if a person can have cannabis-based oil produced by a company (details supplied) collected by an appointed company not for commercial purposes but as a nominated representative or entity collecting the medication strictly on behalf of the person. [21220/19]

Written Answers — Department of Health: Cannabis for Medicinal Use (16 May 2019)

Louise O'Reilly: 114. To ask the Minister for Health further to Parliamentary Question Nos. 826 and 827 of 8 May 2019, if a person can have cannabis-based oil produced by a company (details supplied) collected by an appointed representative strictly on behalf of the person and not for commercial purposes. [21221/19]

Written Answers — Department of Health: Cannabis for Medicinal Use (16 May 2019)

Louise O'Reilly: 115. To ask the Minister for Health further to Parliamentary Question Nos. 826 and 827 of 8 May 2019, if his attention has been drawn to the fact that medical distribution companies are travelling to the Netherlands to collect medicinal cannabis on behalf of patients in Northern Ireland and delivering it to the patients; and the reason a similar arrangement cannot be achieved for patients...

Written Answers — Department of Health: Medicinal Products Regulation (16 May 2019)

Louise O'Reilly: 116. To ask the Minister for Health if a doctor (details supplied) in a remote area will be provided a licence to dispense medicines as was previously the case due to the only pharmacy in the area closing down. [21223/19]